v2.4.1.9
Business Combination - Additional Information (Detail) (USD $)
12 Months Ended 0 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2014
CommercialTests
Jun. 10, 2014
Business Acquisition [Line Items]          
Goodwill acquired in business combination, estimated fair value $ 12,005,000us-gaap_Goodwill $ 0us-gaap_Goodwill   12,005,000us-gaap_Goodwill  
Stock-based compensation 535,000us-gaap_ShareBasedCompensation 72,000us-gaap_ShareBasedCompensation 69,000us-gaap_ShareBasedCompensation    
ImmuMetrix, Inc. [Member]          
Business Acquisition [Line Items]          
Acquisition date Jun. 10, 2014        
Estimated purchase price         17,200,000us-gaap_BusinessCombinationConsiderationTransferred1
/ us-gaap_BusinessAcquisitionAxis
= cdna_ImmumetrixIncMember
Business acquisition purchase price, cash         600,000cdna_BusinessAcquisitionCashConsideration
/ us-gaap_BusinessAcquisitionAxis
= cdna_ImmumetrixIncMember
Milestone description The milestone will be achieved if the Company completes 2,500 commercial tests involving the measurement of cfDNA in organ transplant recipients in the United States no later than six years after the closing date of the acquisition.        
Number of commercial tests involving the measurement of cfDNA to be completed 2,500cdna_NumberOfCommercialTests
/ us-gaap_BusinessAcquisitionAxis
= cdna_ImmumetrixIncMember
    2,500cdna_NumberOfCommercialTests
/ us-gaap_BusinessAcquisitionAxis
= cdna_ImmumetrixIncMember
 
Milestone measurement period 6 years        
Goodwill acquired in business combination, estimated fair value         12,000,000us-gaap_Goodwill
/ us-gaap_BusinessAcquisitionAxis
= cdna_ImmumetrixIncMember
Estimated remaining useful life of patent 15 years        
Business combination pro forma removal (addition) in income tax benefit 1,500,000cdna_BusinessAcquisitionsProFormaAdjustmentIncreaseDecreaseInIncomeTaxExpenseBenefit
/ us-gaap_BusinessAcquisitionAxis
= cdna_ImmumetrixIncMember
1,500,000cdna_BusinessAcquisitionsProFormaAdjustmentIncreaseDecreaseInIncomeTaxExpenseBenefit
/ us-gaap_BusinessAcquisitionAxis
= cdna_ImmumetrixIncMember
     
ImmuMetrix, Inc. [Member] | CareDx, Inc [Member]          
Business Acquisition [Line Items]          
Acquisition-related costs 1,700,000cdna_BusinessAcquisitionCostOfAcquiredEntityTransactionCostsExpensedDuringPeriod
/ us-gaap_BusinessAcquisitionAxis
= cdna_ImmumetrixIncMember
/ dei_LegalEntityAxis
= us-gaap_ParentCompanyMember
       
Stock-based compensation 200,000us-gaap_ShareBasedCompensation
/ us-gaap_BusinessAcquisitionAxis
= cdna_ImmumetrixIncMember
/ dei_LegalEntityAxis
= us-gaap_ParentCompanyMember
       
ImmuMetrix, Inc. [Member] | Contingent consideration [Member]          
Business Acquisition [Line Items]          
Shares issued, shares issuable upon achievement of future milestone, and options assumed       227,845us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
/ us-gaap_BusinessAcquisitionAxis
= cdna_ImmumetrixIncMember
/ us-gaap_ContingentConsiderationByTypeAxis
= cdna_ContingentPaymentMember
 
Milestone description The issuance will occur if the Company completes 2,500 commercial tests involving the measurement of cfDNA in organ transplant recipients in the United States by June 10, 2020.        
ImmuMetrix, Inc. [Member] | In-process technology [Member]          
Business Acquisition [Line Items]          
Assets acquired in business combination, estimated fair value         6,700,000us-gaap_FinitelivedIntangibleAssetsAcquired1
/ us-gaap_BusinessAcquisitionAxis
= cdna_ImmumetrixIncMember
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_InProcessResearchAndDevelopmentMember
Accumulated amortization of intangible asset 0us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
/ us-gaap_BusinessAcquisitionAxis
= cdna_ImmumetrixIncMember
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_InProcessResearchAndDevelopmentMember
    0us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
/ us-gaap_BusinessAcquisitionAxis
= cdna_ImmumetrixIncMember
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_InProcessResearchAndDevelopmentMember
 
ImmuMetrix, Inc. [Member] | Series G Preferred Stock [Member]          
Business Acquisition [Line Items]          
Shares issued, shares issuable upon achievement of future milestone, and options assumed         911,364us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
/ us-gaap_BusinessAcquisitionAxis
= cdna_ImmumetrixIncMember
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesGPreferredStockMember
Estimated fair value         14,200,000us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
/ us-gaap_BusinessAcquisitionAxis
= cdna_ImmumetrixIncMember
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesGPreferredStockMember
ImmuMetrix, Inc. [Member] | Series G Preferred Stock [Member] | Contingent consideration [Member]          
Business Acquisition [Line Items]          
Shares issued, shares issuable upon achievement of future milestone, and options assumed         227,845us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
/ us-gaap_BusinessAcquisitionAxis
= cdna_ImmumetrixIncMember
/ us-gaap_ContingentConsiderationByTypeAxis
= cdna_ContingentPaymentMember
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesGPreferredStockMember
Estimated fair value       1,100,000us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
/ us-gaap_BusinessAcquisitionAxis
= cdna_ImmumetrixIncMember
/ us-gaap_ContingentConsiderationByTypeAxis
= cdna_ContingentPaymentMember
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesGPreferredStockMember
2,300,000us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
/ us-gaap_BusinessAcquisitionAxis
= cdna_ImmumetrixIncMember
/ us-gaap_ContingentConsiderationByTypeAxis
= cdna_ContingentPaymentMember
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesGPreferredStockMember
ImmuMetrix, Inc. [Member] | Series G Preferred Stock [Member] | Stock Options [Member]          
Business Acquisition [Line Items]          
Shares issued, shares issuable upon achievement of future milestone, and options assumed         23,229us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
/ us-gaap_BusinessAcquisitionAxis
= cdna_ImmumetrixIncMember
/ us-gaap_OptionIndexedToIssuersEquityTypeAxis
= us-gaap_EmployeeStockOptionMember
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesGPreferredStockMember
Estimated fair value         $ 369,000us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
/ us-gaap_BusinessAcquisitionAxis
= cdna_ImmumetrixIncMember
/ us-gaap_OptionIndexedToIssuersEquityTypeAxis
= us-gaap_EmployeeStockOptionMember
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesGPreferredStockMember